JP2023512366A5 - - Google Patents

Info

Publication number
JP2023512366A5
JP2023512366A5 JP2021564953A JP2021564953A JP2023512366A5 JP 2023512366 A5 JP2023512366 A5 JP 2023512366A5 JP 2021564953 A JP2021564953 A JP 2021564953A JP 2021564953 A JP2021564953 A JP 2021564953A JP 2023512366 A5 JP2023512366 A5 JP 2023512366A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
brain
brain tissue
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512366A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/050879 external-priority patent/WO2021156769A1/en
Publication of JP2023512366A publication Critical patent/JP2023512366A/ja
Publication of JP2023512366A5 publication Critical patent/JP2023512366A5/ja
Priority to JP2025153760A priority Critical patent/JP2026001009A/ja
Pending legal-status Critical Current

Links

JP2021564953A 2020-02-03 2021-02-03 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法 Pending JP2023512366A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025153760A JP2026001009A (ja) 2020-02-03 2025-09-17 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062969568P 2020-02-03 2020-02-03
US62/969,568 2020-02-03
US202063029154P 2020-05-22 2020-05-22
US63/029,154 2020-05-22
US202063072714P 2020-08-31 2020-08-31
US63/072,714 2020-08-31
PCT/IB2021/050879 WO2021156769A1 (en) 2020-02-03 2021-02-03 Methods for treating neurological symptoms associated with lysosomal storage diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025153760A Division JP2026001009A (ja) 2020-02-03 2025-09-17 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法

Publications (2)

Publication Number Publication Date
JP2023512366A JP2023512366A (ja) 2023-03-27
JP2023512366A5 true JP2023512366A5 (cg-RX-API-DMAC7.html) 2024-02-13

Family

ID=74592326

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564953A Pending JP2023512366A (ja) 2020-02-03 2021-02-03 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
JP2025153760A Pending JP2026001009A (ja) 2020-02-03 2025-09-17 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025153760A Pending JP2026001009A (ja) 2020-02-03 2025-09-17 リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法

Country Status (12)

Country Link
US (1) US12083115B2 (cg-RX-API-DMAC7.html)
EP (1) EP4100009A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023512366A (cg-RX-API-DMAC7.html)
KR (1) KR20220136887A (cg-RX-API-DMAC7.html)
CN (1) CN115427038A (cg-RX-API-DMAC7.html)
AU (1) AU2021215396B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022014553A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166777A1 (cg-RX-API-DMAC7.html)
IL (1) IL295255A (cg-RX-API-DMAC7.html)
MX (1) MX2022009477A (cg-RX-API-DMAC7.html)
TW (1) TW202142236A (cg-RX-API-DMAC7.html)
WO (1) WO2021156769A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
US20250107713A1 (en) * 2023-09-29 2025-04-03 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods for Confirming Iboga Alkaloid Treatment
WO2025219952A1 (en) * 2024-04-19 2025-10-23 Genzyme Corporation Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders
TW202604489A (zh) * 2024-04-19 2026-02-01 美商健臻公司 用於降低患有神經節苷脂儲積症的患者中的疾病相關生物標誌物水準之方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB725228A (en) 1952-06-19 1955-03-02 Roche Products Ltd Substituted carbamic acid esters and process for the manufacture thereof
BE640616A (cg-RX-API-DMAC7.html) 1962-12-19
NL130759C (cg-RX-API-DMAC7.html) 1965-10-07
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4593034A (en) 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
IE63474B1 (en) 1987-12-24 1995-04-19 Wyeth John & Brother Ltd Heterocyclic compounds
ATE85217T1 (de) 1988-08-04 1993-02-15 Synthelabo Antischizophren-wirksame s-n-(1-azabicyclo (2.2.2.>oct-3-yl)benzamide und thiobenzamide.
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
IT1228293B (it) 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
GB9106571D0 (en) 1991-03-27 1991-05-15 Erba Carlo Spa Derivatives of substituted imidazol-2-one and process for their preparation
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
AU685225B2 (en) 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
JPH08198751A (ja) 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
JP2000500139A (ja) 1995-11-08 2000-01-11 アメリカン・ホーム・プロダクツ・コーポレイション 1−アザビシクロヘプタン誘導体およびそれらの医薬用途
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
EE9900034A (et) 1996-07-29 1999-08-16 Pharmacia & Upjohn Ab Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
EP1027069B1 (en) 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
CN1332726A (zh) 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
PL357099A1 (en) 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
AU2001266100B9 (en) 2000-06-27 2005-10-06 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
DE60216830T2 (de) 2001-02-06 2007-06-14 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
JP2003267977A (ja) 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2393331T3 (es) 2002-07-17 2012-12-20 Actelion Pharmaceuticals Ltd. Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa
AU2003248122A1 (en) 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
ATE378048T1 (de) 2002-12-06 2007-11-15 The Feinstein Inst Medical Res Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200529860A (en) 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
JP2007186422A (ja) 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体
JP2008504282A (ja) 2004-06-23 2008-02-14 ザ ファインスタイン インスティテュート フォー メディカル リサーチ コリンレセプターの薬理活性により腸閉塞を処置する方法
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
EP1891048A1 (en) 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN101312968A (zh) 2005-09-23 2008-11-26 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途
SG131819A1 (en) 2005-11-07 2007-05-28 Chikka Pte Ltd Buddy-based cross-carrier messaging system
JP2009523845A (ja) 2006-01-23 2009-06-25 クリスタルゲノミクス インコーポレーテッド たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物
US20090318491A1 (en) 2006-01-27 2009-12-24 Yale Univeristy Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders
WO2008096870A1 (ja) 2007-02-09 2008-08-14 Astellas Pharma Inc. アザ架橋環化合物
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
CA2707360A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
EP2211856A4 (en) 2007-11-29 2011-02-09 Hospital For Sick Children COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER
JP2011529500A (ja) 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
WO2010091164A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
CN102438988B (zh) 2009-04-21 2015-06-24 内尔维阿诺医学科学有限公司 作为hsp90抑制剂的间苯二酚衍生物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2456438A2 (en) 2009-07-23 2012-05-30 Novartis AG Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
CA2773133A1 (en) 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
AU2011327113B9 (en) 2010-11-12 2015-07-30 Shionogi & Co., Ltd. Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
LT2685986T (lt) 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
US20140228575A1 (en) 2011-06-22 2014-08-14 Isochem Process for the Preparation of Solifenacin and Salts Thereof
AU2012272815B2 (en) 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
PL4066849T3 (pl) 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
TW201900625A (zh) 2013-03-15 2019-01-01 美商健臻公司 製備葡糖基神經醯胺合成酶抑制劑之方法
EP3079695B1 (en) 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
EP3412296B1 (en) * 2016-02-05 2025-11-12 Kyungpook National University Industry-Academic Cooperation Foundation Pharmaceutical composition containing stem cell in which vascular endothelial growth factor is overexpressed as effective ingredient for preventing or treating neurodegenerative disease
JP7585561B2 (ja) * 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
SG11202107844UA (en) 2019-02-04 2021-08-30 Genzyme Corp Methods for treating symptoms and disorders associated with lysosomal storage diseases
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases

Similar Documents

Publication Publication Date Title
US10543179B2 (en) Dosage regimen of an S1P receptor modulator
JP2003510273A (ja) 神経障害性の疼痛の治療のためのレチガビンの使用
EP1948177B1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US10285981B2 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
JP2012500800A (ja) 神経因性疼痛の治療法
US20250288544A1 (en) Probenecid for use in treating epileptic diseases, disorders or conditions
JP2021152060A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
US20060241133A1 (en) Electrically variable pneumatic structural element
JP7337081B2 (ja) レストレスレッグズ症候群を治療するための治療薬
TW202231661A (zh) 安全投予抗tau抗體之方法
CN117244056A (zh) 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
WO2018023036A1 (en) Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment
ES2316808T3 (es) Empleo de dihidroimidazolonas para el tratamiento de la epilepsia en perros.
TWI864376B (zh) 焦慮症處置用組成物及處置方法
CN113242735A (zh) 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
RU2785842C2 (ru) Применение пробенецида для лечения эпилептических заболеваний, нарушений и состояний
ES2199541T3 (es) Aplicacion del 2-amino-6-trifluorometoxi-benzotiazol para la prevencion o el tratamiento de disfunciones del cerebelo.
JP2007523827A (ja) 混合性白血病遺伝子の再構成を伴う急性リンパ芽球性白血病の処置方法
US20170112789A1 (en) Intravenous baclofen and methods of treatment
CA3070178C (en) Probenecid for use in treating epileptic diseases, disorders or conditions
US6153638A (en) Use of efaroxan for producing medicine for treating huntington 's disease
TW202510848A (zh) 用於治療癌症之psma靶向放射性藥物
CN119384295A (zh) 以纹状体纹状小体的多巴胺d1信号为靶点的强迫性障碍的药物疗法
EA048938B1 (ru) Комбинация антагониста cxcr7 с модулятором рецептора s1p1
US20190038624A1 (en) Use of abelson tyrosine kinase inhibitor in treatment of multiple system atrophy